atractylenolide iii has been researched along with docetaxel anhydrous in 1 studies
| Studies (atractylenolide iii) | Trials (atractylenolide iii) | Recent Studies (post-2010) (atractylenolide iii) | Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) |
|---|---|---|---|---|---|
| 86 | 0 | 62 | 12,110 | 3,216 | 6,920 |
| Protein | Taxonomy | atractylenolide iii (IC50) | docetaxel anhydrous (IC50) |
|---|---|---|---|
| Kinesin-like protein KIF11 | Homo sapiens (human) | 0.0014 | |
| Nucleotide-binding oligomerization domain-containing protein 2 | Homo sapiens (human) | 5.0119 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Guo, Q; Ji, Y; Kang, N; Kang, Z; Zhao, Y | 1 |
1 other study(ies) available for atractylenolide iii and docetaxel anhydrous
| Article | Year |
|---|---|
Atractylenolide III Enhances the Anti-Neoplastic Efficacy of Docetaxel in Gastric Cancer Cell by Inhibiting Fibroblast Growth Factor Receptors 1, -2, and -4 Expression.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Gene Expression; Humans; Lactones; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 4; Sesquiterpenes; Stomach Neoplasms | 2019 |